文献速递乳腺癌

70岁及以上三阴性乳腺癌女性在局部治疗基础上加化疗的倾向匹配分析

Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.
PubMed 文献 · Lancet Oncol · 2020-01-01

该研究基于美国国家癌症数据库2004—2014年数据,纳入16 062例70岁及以上、手术治疗的I–III期三阴性乳腺癌女性,采用多因素Cox回归和倾向评分匹配分析加化疗对总生存的影响。

要点

  • 70岁及以上三阴性乳腺癌患者接受化疗与总生存改善相关。
  • 淋巴结阴性与阳性、合并症评分>0者均可见生存获益。

核心结论

  • 这些数据支持在70岁及以上三阴性乳腺癌女性中考虑化疗。

研究设计与样本

  • 倾向匹配分析,使用美国国家癌症数据库数据。
  • 纳入2004—2014年诊断、70岁及以上、手术治疗的AJCC I–III期浸润性三阴性乳腺癌女性。
  • 排除T1aN0M0及雌激素受体、孕激素受体或HER2状态数据不完整者。
  • 采用多因素Cox回归和倾向评分匹配以减少偏倚。

临床怎么用

  • 对70岁及以上、手术治疗的I–III期三阴性乳腺癌女性,可与患者讨论在局部治疗基础上加化疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a scarcity of data exploring the benefits of adjuvant or neoadjuvant chemotherapy in the treatment of breast cancer in older women. We aimed to explore the effect of adding chemotherapy to local therapy on overall survival in older women with triple-negative breast cancer. METHODS: For this propensity-matched analysis, we used data from the National Cancer Database, a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. We included data from women aged 70 years or older with surgically treated, American Joint Committee on Cancer (AJCC) Stage I-III invasive triple-negative breast cancer diagnosed from 2004 to 2014. Patients with T1aN0M0 disease and those with incomplete data on oestrogen receptor status, progesterone receptor status, or HER2 status were excluded. To reduce bias, patients were subdivided into three groups: those who were recommended chemotherapy but did not receive it; those who received chemotherapy; and those for whom chemotherapy was not recommended and not given. The primary outcome was overall survival. Multivariate Cox regression analysis and propensity score matching were done to minimise bias. FINDINGS: Between Jan 1, 2004, and Dec, 31, 2014, 16 062 women with triple-negative breast cancer in the database met the inclusion criteria for this analysis. Median follow-up was 38·3 months (IQR 20·7-46·1, range 0-138·0; 95% CI 37·8-38·7). Collectively, the 5-year overall survival estimate of the 16 062 patients in the study cohort was 62·3% (95% CI 59·7-64·4). 5-year estimated overall survival was 68·5% (95% CI 66·4-70·6) for patients receiving chemotherapy, 61·1% (59·0-63·2) for patients recommended but not given chemotherapy, and 53·7% (51·8-55·8) for patients not recommended chemotherapy and not given chemotherapy (pooled log rank p<0·0001). Multivariate Cox regression analysis of a propensity score-matched sample comparing those who received chemotherapy with those who were recommended but not given chemotherapy (n=1884 matched pairs) identified improved overall survival with chemotherapy (hazard ratio [HR] 0·69 [95% CI 0·60-0·80]; p<0·0001). After stratifying the propensity score matching sample, this benefit persisted for node-negative women (HR 0·80 [95% CI 0·66-0·97]; p=0·007), node-positive women (0·76 [0·64-0·91]; p=0·006), and those with a comorbidity score greater than 0 (HR 0·74 [95% CI 0·59-0·94]; p=0·013). INTERPRETATION: These data support consideration of chemotherapy in the treatment of women aged 70 years or older with triple-negative breast cancer. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Crozier JA, Pezzi TA, Hodge C, et al. Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis. Lancet Oncol. 2020. PMID: 33271091. doi:10.1016/S1470-2045(20)30538-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。